TIDMPRM

RNS Number : 8662T

Proteome Sciences PLC

30 March 2021

30 March 2021

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Loan amendment

On 3 July 2018, the Company entered into a GBP1 million loan facility with Vulpes Investment Management Private Limited ("VIM") (the "Loan"). The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which GBP700,000 is currently drawn) and all accrued interest is now repayable on 1 May 2022 (previously 1 May 2021) (the "Loan Amendment"). All other terms of the Loan remain the same as announced on 3 July 2018, including that interest will accrue at the annual rate of 2.5 per cent. above the UK sterling base rate of Barclays Bank plc.

Mr Martin Diggle, Non-Executive Director of Proteome Sciences, is a director and partner of VIM. VIM manages the Vulpes Life Sciences Fund, which is the shareholder of 22.3 per cent. of Proteome Sciences. By virtue of Mr Diggle being a director of the Company and a partner and director of VIM, the Loan Amendment constitutes a related party transaction in accordance with the AIM Rules for Companies. Accordingly, the directors independent of the transaction, being all directors of the Company save for Mr Diggle, consider, having consulted with the Company's nominated adviser, that the Loan Amendment is fair and reasonable insofar as the Company's shareholders are concerned.

For further information please contact:

 
 Proteome Sciences plc 
 
  Mariola Soehngen, M.D., Chief Executive Officer 
 Dr Ian Pike, Chief Scientific Officer      Tel: +44 (0)20 7043 2116 
 Richard Dennis, Chief Commercial Officer 
 
 Allenby Capital Limited (AIM Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter            Tel: +44 (0) 20 3328 5656 
 

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUKUNRAWUOUAR

(END) Dow Jones Newswires

March 30, 2021 02:00 ET (06:00 GMT)

Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Proteome Sciences.
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Proteome Sciences.